Interleukin-35 as a predictor of prostate cancer in patients undergoing initial prostate biopsy

OncoTargets and Therapy Aug 12, 2017

Zhou C, et al. – The role of plasma interleukin (IL)–35 was contemplated here, in the diagnosis and prognosis of prostate cancer (PCa), among Chinese patients undergoing initial prostate biopsy. An association was brought to light between plasma IL–35 levels with PCa. It served as the independent predictor of PCa progression and metastasis. Therefore, IL–35 could be utilized as a potential biomarker for diagnosis and prognosis of PCa. It would also assist in decision making and would predict the stage of the disease.
Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
  • 55 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Unlimited access to original articles by experts
  • Nonloggedinlock icon
    Secure: we never sell your data
  • Signing up takes less than 2 mins
Try M3 India / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen